These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20484464)

  • 1. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
    Chen H; Dardik B; Qiu L; Ren X; Caplan SL; Burkey B; Boettcher BR; Gromada J
    Endocrinology; 2010 Jul; 151(7):3115-24. PubMed ID: 20484464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
    Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
    Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
    Fu J; Oveisi F; Gaetani S; Lin E; Piomelli D
    Neuropharmacology; 2005 Jun; 48(8):1147-53. PubMed ID: 15910890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
    Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
    Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Jung HY; Kim B; Ryu HG; Ji Y; Park S; Choi SH; Lee D; Lee IK; Kim M; Lee YJ; Song W; Lee YH; Choi HJ; Hyun CK; Holzapfel WH; Kim KT
    Diabetes Obes Metab; 2018 Jul; 20(7):1688-1701. PubMed ID: 29516607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
    Hu X; Feng Y; Shen Y; Zhao XF; Yu JH; Yang YS; Leng Y
    Acta Pharmacol Sin; 2006 Oct; 27(10):1346-52. PubMed ID: 17007742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice.
    Cornick CL; Strongitharm BH; Sassano G; Rawlins C; Mayes AE; Joseph AN; O'Dowd J; Stocker C; Wargent E; Cawthorne MA; Brown AL; Arch JR
    J Nutr Biochem; 2009 Oct; 20(10):806-15. PubMed ID: 18926687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
    Ide T; Tsunoda M; Mochizuki T; Murakami K
    Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
    Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
    Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
    Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.